A Civil Society Response to the Big Pharma wish list in TTIP

The analysis of the most worrying proposals of the pharmaceutical industry's wish list for the EU-US trade agreement reveals a real threat to European public health systems and democracy. 

Joint position paper produced by Commons Network in cooperation with Medicines in Europe Forum (MiEF), International Society of Drug Bulletins (ISDB), Health Action International Europe (HAI-Europe), Universities Allied for Essential Medicines - Europe (UAEM-Europe), Salud por Derecho Foundation and The Working Group on Health, Medicines & Innovation (GTSMI).


European Medicines Agency (EMA) softens its conflict of interest policy: Does this further open the door to undue influence instead of closing it?

28 November 2014 

Joint Press Release

At the end of November 2014, the European Medicines Agency has announced the adoption of a “more balanced approach to handling conflicts of interests” to become effective on 30 January 2015. In reality, this revised EMA COI policy relaxes EMA’s position in relation to the conflicts of interest of experts with pharmaceutical companies. The evaluation of the efficacy and harms of medicines must be free from undue influence and be based on scientific data, so that the Agency’s work can benefit public health. The Agency’s integrity is at stake